A global pharmaceutical company, Teva develops, produces, and markets generic drugs covering all major treatment categories.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
TEVA at 36!? Are you kidding me!....this company makes 80% of their revenues from generics! Deals in 32 currencies around the world, has industry leading world wide manufacturing, first to file on many near patent expiry drugs, and has spent significant amounts on producing biosimilars producing cap ex- the future of generic biotech is huge! This doesn't even include their pipeline acquired from Cephalon.
TEVA is my largest holding. Yes, in hindsight, I'm wishing I would have waited until now to begin buying it. Mr. Market is depressed by the negative headlines surrounding Copaxone and Liquinimod. I bought TEVA for the generics business, not for the higher-risk new drug development. I just can't bet against generics for the long term as consumers and governments try to save money on health care.
One thing I've learned: if you buy a stock and are happy when it soon goes lower, you are investing. If you buy a stock and are upset when it soon goes lower, you are speculating. So while I'm happy that this stock is "even cheaper" than when I bought it back in the $55-$60 range, I can't help but wish I would have waited. One of the biases I have is "jumping in too soon." I wasn't aware of the significant "headline risk" involved with TEVA stock.
I still can't bet against this stock for the long run. Generic drugs aren't going away and as global populations age, more and more will be needed. Emerging market demand will increase rapidly as basic health care will be one of the first priorities. TEVA is an "emerging market" play that is currently out of favor from all of the negative headlines. It may be "efficiently priced" for the short term, but I believe it is mispriced for the longer term.
50% of the NA population and more in Japan will be of the age of 65 over the course of the next 20 years. The wind will be at their backs. The entry in Biosimilars is very exciting as NA doesn't even have rules regarding biologic generics yet. The moons are aligned for this company, but the Mr. Market has thrown this in the garbage with the other branded drug companies with expiring patents.
Yup.... TEVA looks extremely cheap. It wouldn't have been on my radar but I seen it when I was thumbing thru value line at the library.
Strong buy! The technical analysis is all for it. Plus ... just how much cheaper the generic Copaxone can be when introduced to the markets?
Tevas dividends grew ten folds in a past ten years.!